2024
Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
Zhang T, Yu W, Cheng X, Yeung J, Ahumada V, Norris P, Pearson M, Yang X, van Deursen W, Halcovich C, Nassar A, Vesely M, Zhang Y, Zhang J, Ji L, Flies D, Liu L, Langermann S, LaRochelle W, Humphrey R, Zhao D, Zhang Q, Zhang J, Gu R, Schalper K, Sanmamed M, Chen L. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity. Science Immunology 2024, 9: eadh2334. PMID: 38669316, DOI: 10.1126/sciimmunol.adh2334.Peer-Reviewed Original ResearchConceptsT cell infiltrationT cell exclusionT cellsResistance to anti-PD-1 immunotherapyPoor T-cell infiltrationAnti-PD-1 immunotherapyImmunogenic mouse tumorsT cell mobilizationHuman cancer tissuesTherapeutic immunotherapyCancer immunotherapyMouse tumorsChemokine systemImmunotherapyTumor tissuesImpaired infiltrationTumorLipid metabolitesHuman cancersCancer tissuesInfiltrationA2 groupCancerPLA2G10Up-regulated
2012
Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State
Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ. Opposing Roles for IL-23 and IL-12 in Maintaining Occult Cancer in an Equilibrium State. Cancer Research 2012, 72: 3987-3996. PMID: 22869585, PMCID: PMC4384890, DOI: 10.1158/0008-5472.can-12-1337.Peer-Reviewed Original ResearchConceptsIL-12IL-23Antibody treatmentImmune systemCD40 antibody treatmentIL‐12/23p40 antibodiesAutoimmune inflammatory disorderMonoclonal antibody treatmentOccult neoplasiaOccult cancerIL-17IL-23p19IL-12/23p40Immune controlInflammatory disordersTumor immunogenicityIL-4Malignant potentialCancer immunoeditingTumor outgrowthElimination phaseTumor growthTumor dormancyMutant cancersCancer cells
2008
Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2008, 105: 652-656. PMID: 18178624, PMCID: PMC2206591, DOI: 10.1073/pnas.0708594105.Peer-Reviewed Original ResearchConceptsCancer immunoeditingWT controlsAdaptor myeloid differentiation factor 88Myeloid differentiation factor 88Adaptive immune surveillanceMyD88-/- miceMyD88-deficient miceRole of TNFDMBA/TPAInflammation-induced cancerDistinct mouse modelsTNF-deficient miceInflammation-induced carcinogenesisO-tetradecanoylphorbol 13Mouse tumor modelsFactor 88WT miceChronic inflammationMCA sarcomaProinflammatory processesTumor immunologistsImmune surveillanceMouse modelSkin papillomasPrimary tumorigenesis